Artisan Pharma

Artisan Pharma, Inc., is a biopharmaceutical company focused on pioneering critical-care therapeutics to enhance patient outcomes globally. The company's slogan "Pioneering critical-care therapeutics to enhance patient outcomes globally" encapsulates their mission to make a significant impact in the field of healthcare. Founded in 2006 and headquartered in Waltham, Massachusetts, Artisan Pharma specializes in providing critical-care and hospital-based therapeutics to patients, treating physicians, and payors both in the United States and internationally. Artisan Pharma's flagship product is ART-123, a novel recombinant and soluble thrombomodulin designed specifically for treating disseminated intravascular coagulation in sepsis. The company has successfully marketed its products in significant regions including Japan, China, Taiwan, and Korea, demonstrating a global expansion strategy. Moreover, their strategic manufacturing alliance with A-Bio Pharma Pte Ltd enables efficient production and distribution of their groundbreaking therapeutics. In terms of investments, Artisan Pharma secured a notable $3.00M Series C investment on 20 July 2010, attracting major investors such as EDBI, New Leaf Venture Partners, Novaquest Capital Management, and NGN Capital. These investments reflect the attractiveness and potential of the company’s innovative approach to improving critical-care treatment. Overall, Artisan Pharma appears to be in a strong position to continue its impactful work in critical-care therapeutics, while also presenting an intriguing opportunity for potential venture capital partners seeking to invest in the biopharmaceutical industry.